home / stock / vyne / vyne quote
Last: | $1.84 |
---|---|
Change Percent: | 4.07% |
Open: | $1.7555 |
Close: | $1.84 |
High: | $1.85 |
Low: | $1.751 |
Volume: | 16,113 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.84 | $1.7555 | $1.84 | $1.85 | $1.751 | 16,113 | 07-05-2024 |
$1.83 | $1.84 | $1.83 | $1.9085 | $1.75 | 21,767 | 07-04-2024 |
$1.83 | $1.84 | $1.83 | $1.9085 | $1.75 | 21,767 | 07-03-2024 |
$1.81 | $1.86 | $1.81 | $1.93 | $1.81 | 28,518 | 07-02-2024 |
$1.92 | $1.95 | $1.92 | $1.95 | $1.9 | 8,162 | 07-01-2024 |
$1.97 | $1.9 | $1.97 | $1.98 | $1.75 | 73,092 | 06-28-2024 |
$1.97 | $1.62 | $1.97 | $1.98 | $1.57 | 101,101 | 06-27-2024 |
$1.6 | $1.71 | $1.6 | $1.755 | $1.59 | 64,215 | 06-26-2024 |
$1.73 | $1.84 | $1.73 | $1.93 | $1.72 | 55,390 | 06-25-2024 |
$1.73 | $1.83 | $1.73 | $1.95 | $1.72 | 116,796 | 06-24-2024 |
$1.82 | $1.75 | $1.82 | $1.9 | $1.74 | 116,267 | 06-21-2024 |
$1.74 | $2.21 | $1.74 | $2.26 | $1.7112 | 472,804 | 06-20-2024 |
$2.21 | $2.3817 | $2.21 | $2.3817 | $2.21 | 17,922 | 06-19-2024 |
$2.21 | $2.3817 | $2.21 | $2.3817 | $2.21 | 17,922 | 06-18-2024 |
$2.36 | $2.33 | $2.36 | $2.42 | $2.15 | 68,139 | 06-17-2024 |
$2.3 | $2.19 | $2.3 | $2.31 | $2.05 | 23,218 | 06-14-2024 |
$2.2 | $2.2153 | $2.2 | $2.3076 | $2 | 96,980 | 06-13-2024 |
$2.15 | $2.29 | $2.15 | $2.36 | $2.11 | 94,654 | 06-12-2024 |
$2.29 | $2.316 | $2.29 | $2.3495 | $2.2 | 28,660 | 06-11-2024 |
$2.28 | $2.25 | $2.28 | $2.365 | $2.1387 | 40,567 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line data expected in 2H’24 BRIDGEWATER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- ...
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 BRIDGEWATER, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (...